214450 — PharmaResearch Co Income Statement
0.000.00%
Last trade - 00:00
- KR₩1tn
- KR₩1tn
- KR₩261bn
- 91
- 26
- 62
- 67
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 83,872 | 108,746 | 154,083 | 194,759 | 261,011 |
Cost of Revenue | |||||
Gross Profit | 50,106 | 72,896 | 108,333 | 141,513 | 190,258 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 65,075 | 76,571 | 102,434 | 133,954 | 171,873 |
Operating Profit | 18,797 | 32,175 | 51,649 | 60,805 | 89,138 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 18,529 | 39,537 | 56,033 | 54,048 | 100,705 |
Provision for Income Taxes | |||||
Net Income After Taxes | 14,851 | 32,452 | 46,824 | 43,434 | 77,265 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 16,667 | 32,774 | 46,689 | 40,577 | 76,551 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | 16,667 | 32,774 | 47,397 | 43,603 | 79,056 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 1,788 | 3,587 | 4,766 | 4,534 | 7,711 |
Dividends per Share |